Updates

Clinigen - First of half a dozen deals

April 2013

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

After the wait, not one but two hospital drugs were acquired in March. Bigger of the two is the purchase of oncology support therapy Cardioxane (dexrazoxane) from Novartis for US$33m in cash, payable in two tranches. Cardioxane is used to minimise heart damage caused by a commonly-used class of chemotherapy drug called anthracyclines, and it is indicated for use specifically in advanced breast cancer. Under the agreement, Clinigen will assume all responsibilities for the drug, which is presently sold in Europe, Asia and Latin America. Historic revenues for Cardioxane are c.US$11m annually but broker Numis reckons Clinigen will double this by 2017 whilst standardising the pricing will also see margins rise from 40% to 60%. ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Parity - Await first of many deals on digital solutions side

SQS - Managed services now 34% of work

Clinigen (November 2016)

Clinigen (October 2016)

Clinigen (October 2015)

Clinigen (August 2015)

Clinigen - Completes £225m Idis acquisition (June 2015)

Clinigen (April 2015)

Clinigen (February 2015)

Clinigen - Acquires speciality products (September 2014)

Clinigen - Company reassures investors with trading update (August 2014)

Clinigen (March 2014)

Clinigen - Growing rapidly into valuation (February 2014)

Clinigen - On lookout for 3-5 more deals (November 2013)

Clinigen - Another upgrade to forecast (September 2013)

Clinigen - Acquisition anticipated in March (March 2013)

Clinigen - Trial services to grow at 17% annual clip (December 2012)

Clinigen - New issue growing like topsy (November 2012)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X